JP6053283B2 - 放射線被曝の処置のための組成物および方法 - Google Patents
放射線被曝の処置のための組成物および方法 Download PDFInfo
- Publication number
- JP6053283B2 JP6053283B2 JP2011530016A JP2011530016A JP6053283B2 JP 6053283 B2 JP6053283 B2 JP 6053283B2 JP 2011530016 A JP2011530016 A JP 2011530016A JP 2011530016 A JP2011530016 A JP 2011530016A JP 6053283 B2 JP6053283 B2 JP 6053283B2
- Authority
- JP
- Japan
- Prior art keywords
- radiation
- composition
- mdp
- microparticles
- mdp microparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 104
- 206010073306 Exposure to radiation Diseases 0.000 title claims description 60
- 238000011282 treatment Methods 0.000 title claims description 55
- 238000000034 method Methods 0.000 title description 71
- 239000011859 microparticle Substances 0.000 claims description 279
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 234
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 231
- 230000005855 radiation Effects 0.000 claims description 148
- 231100000572 poisoning Toxicity 0.000 claims description 65
- 230000000607 poisoning effect Effects 0.000 claims description 65
- 102000004127 Cytokines Human genes 0.000 claims description 40
- 108090000695 Cytokines Proteins 0.000 claims description 40
- 239000003446 ligand Substances 0.000 claims description 39
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 37
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 37
- 238000001959 radiotherapy Methods 0.000 claims description 35
- 230000005865 ionizing radiation Effects 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 28
- 238000011084 recovery Methods 0.000 claims description 24
- 102000004889 Interleukin-6 Human genes 0.000 claims description 21
- 108090001005 Interleukin-6 Proteins 0.000 claims description 21
- 230000037396 body weight Effects 0.000 claims description 21
- 229940100601 interleukin-6 Drugs 0.000 claims description 21
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 20
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 20
- 210000001772 blood platelet Anatomy 0.000 claims description 20
- 210000001185 bone marrow Anatomy 0.000 claims description 20
- 102000000589 Interleukin-1 Human genes 0.000 claims description 19
- 108010002352 Interleukin-1 Proteins 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 102000000646 Interleukin-3 Human genes 0.000 claims description 17
- 108010002386 Interleukin-3 Proteins 0.000 claims description 17
- 229940076264 interleukin-3 Drugs 0.000 claims description 17
- 230000003394 haemopoietic effect Effects 0.000 claims description 15
- 230000001737 promoting effect Effects 0.000 claims description 15
- 210000003743 erythrocyte Anatomy 0.000 claims description 12
- 230000003308 immunostimulating effect Effects 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 210000000265 leukocyte Anatomy 0.000 claims description 10
- 230000004936 stimulating effect Effects 0.000 claims description 10
- 210000000278 spinal cord Anatomy 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 7
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 claims description 7
- 108010029961 Filgrastim Proteins 0.000 claims description 6
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 6
- UVJDUBUJJFBKLD-UHFFFAOYSA-L zinc;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;hydron Chemical compound [H+].[H+].[H+].[Zn+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)CC([O-])=O UVJDUBUJJFBKLD-UHFFFAOYSA-L 0.000 claims description 6
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 5
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 claims description 5
- 238000011262 co‐therapy Methods 0.000 claims description 5
- 229960004177 filgrastim Drugs 0.000 claims description 5
- 230000002519 immonomodulatory effect Effects 0.000 claims description 5
- 230000003449 preventive effect Effects 0.000 claims description 5
- 101000839034 Giardia intestinalis (strain P15) Flavohemoprotein-1 Proteins 0.000 claims description 4
- 101000839032 Giardia intestinalis (strain P15) Flavohemoprotein-2 Proteins 0.000 claims description 4
- 238000010322 bone marrow transplantation Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000010894 electron beam technology Methods 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 210000002850 nasal mucosa Anatomy 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 102000007863 pattern recognition receptors Human genes 0.000 claims description 4
- 108010089193 pattern recognition receptors Proteins 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 58
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 231100000636 lethal dose Toxicity 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 231100001160 nonlethal Toxicity 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 239000002262 Schiff base Substances 0.000 description 3
- 150000004753 Schiff bases Chemical class 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 2
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 2
- -1 IL -3 Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 208000019155 Radiation injury Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 231100001018 bone marrow damage Toxicity 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 229940073329 radiogardase Drugs 0.000 description 2
- 229940124553 radioprotectant Drugs 0.000 description 2
- 230000001950 radioprotection Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 231100000075 skin burn Toxicity 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MWTAHJPEYZBMCZ-FLLNTKIGSA-N (2s)-2-aminopropanoic acid;(4r)-4,5-diamino-5-oxopentanoic acid Chemical compound C[C@H](N)C(O)=O.NC(=O)[C@H](N)CCC(O)=O MWTAHJPEYZBMCZ-FLLNTKIGSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010000372 Accident at work Diseases 0.000 description 1
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229910052695 Americium Inorganic materials 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229910052685 Curium Inorganic materials 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 240000001973 Ficus microcarpa Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 1
- 229910052778 Plutonium Inorganic materials 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 231100000818 accidental exposure Toxicity 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- LXQXZNRPTYVCNG-UHFFFAOYSA-N americium atom Chemical compound [Am] LXQXZNRPTYVCNG-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- AYFCVLSUPGCQKD-UHFFFAOYSA-L calcium;trisodium;2-[bis[2-[bis(carboxylatomethyl)azaniumyl]ethyl]azaniumyl]acetate Chemical compound [Na+].[Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC(=O)[O-])CC[NH+](CC([O-])=O)CC([O-])=O AYFCVLSUPGCQKD-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940083701 pentetate zinc trisodium Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OYEHPCDNVJXUIW-UHFFFAOYSA-N plutonium atom Chemical compound [Pu] OYEHPCDNVJXUIW-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 208000006934 radiodermatitis Diseases 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- HVASDHJNLYRZEA-UHFFFAOYSA-I trisodium;zinc;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate Chemical compound [Na+].[Na+].[Na+].[Zn+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)CC([O-])=O HVASDHJNLYRZEA-UHFFFAOYSA-I 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1094—Shielding, protecting against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ571665A NZ571665A (en) | 2008-09-30 | 2008-09-30 | Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles |
| NZ571665 | 2008-09-30 | ||
| PCT/NZ2009/000207 WO2010039048A1 (en) | 2008-09-30 | 2009-09-30 | Compositions and methods for treatment of radiation exposure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015160135A Division JP2016026157A (ja) | 2008-09-30 | 2015-08-14 | 放射線被曝の処置のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504161A JP2012504161A (ja) | 2012-02-16 |
| JP2012504161A5 JP2012504161A5 (enExample) | 2012-11-15 |
| JP6053283B2 true JP6053283B2 (ja) | 2016-12-27 |
Family
ID=42073685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530016A Expired - Fee Related JP6053283B2 (ja) | 2008-09-30 | 2009-09-30 | 放射線被曝の処置のための組成物および方法 |
| JP2015160135A Pending JP2016026157A (ja) | 2008-09-30 | 2015-08-14 | 放射線被曝の処置のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015160135A Pending JP2016026157A (ja) | 2008-09-30 | 2015-08-14 | 放射線被曝の処置のための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10232010B2 (enExample) |
| EP (1) | EP2349311B1 (enExample) |
| JP (2) | JP6053283B2 (enExample) |
| CN (1) | CN102170898A (enExample) |
| AU (1) | AU2009300442B2 (enExample) |
| BR (1) | BRPI0913783A2 (enExample) |
| CA (1) | CA2738622C (enExample) |
| ES (1) | ES2435438T3 (enExample) |
| NZ (1) | NZ571665A (enExample) |
| WO (1) | WO2010039048A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2926507A1 (en) * | 2015-10-06 | 2017-04-06 | Innate Immunotherapeutics Limited | Compositions and methods for protection and/or repair of the nervous system |
| WO2017059486A1 (en) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of epilepsy |
| WO2017070731A1 (en) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of alzheimer's disease |
| CN108273038B (zh) * | 2018-03-16 | 2019-03-19 | 中国人民解放军军事科学院军事医学研究院 | 防治肠型放射病的药物组合物 |
| CN111060697A (zh) * | 2019-02-24 | 2020-04-24 | 中国疾病预防控制中心辐射防护与核安全医学所 | 一种利用hmgb1的小肠放射性损伤标记方法 |
| WO2022150763A1 (en) * | 2021-01-11 | 2022-07-14 | The George Washington University | Nanoparticle-mediated immune cell manufacture and uses thereof |
| TWI843989B (zh) | 2021-02-19 | 2024-06-01 | 美商美威高能離子醫療系統公司 | 用於粒子治療系統之支架 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4815446A (en) * | 1985-05-09 | 1989-03-28 | Alpha Therapeutic Corporation | Process for treating metastasis of cancerous tumors |
| AU686660B2 (en) * | 1993-08-11 | 1998-02-12 | Jenner Technologies | Prostatic cancer vaccine |
| GB9320820D0 (en) * | 1993-10-08 | 1993-12-01 | Biokine Tech Ltd | Compounds for medicinal use |
| CA2268372C (en) * | 1996-10-10 | 2012-11-27 | Probe International | Compositions and methods for treating viral infections |
| CA2315115C (en) | 1998-10-23 | 2007-03-20 | Polyheal Ltd. | Compositions of microspheres for wound healing |
| JP5662309B2 (ja) * | 2008-04-01 | 2015-01-28 | イネイト・イムノセラピューティクス・リミテッド | 腫瘍性疾患を治療するための組成物および方法 |
-
2008
- 2008-09-30 NZ NZ571665A patent/NZ571665A/en not_active IP Right Cessation
-
2009
- 2009-09-30 EP EP09818038.3A patent/EP2349311B1/en not_active Not-in-force
- 2009-09-30 JP JP2011530016A patent/JP6053283B2/ja not_active Expired - Fee Related
- 2009-09-30 CA CA2738622A patent/CA2738622C/en not_active Expired - Fee Related
- 2009-09-30 US US13/121,796 patent/US10232010B2/en not_active Expired - Fee Related
- 2009-09-30 CN CN2009801387748A patent/CN102170898A/zh active Pending
- 2009-09-30 ES ES09818038T patent/ES2435438T3/es active Active
- 2009-09-30 AU AU2009300442A patent/AU2009300442B2/en not_active Ceased
- 2009-09-30 BR BRPI0913783A patent/BRPI0913783A2/pt not_active Application Discontinuation
- 2009-09-30 WO PCT/NZ2009/000207 patent/WO2010039048A1/en not_active Ceased
-
2015
- 2015-08-14 JP JP2015160135A patent/JP2016026157A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20110236346A1 (en) | 2011-09-29 |
| EP2349311A4 (en) | 2012-07-04 |
| CA2738622A1 (en) | 2010-04-08 |
| EP2349311B1 (en) | 2013-08-21 |
| CN102170898A (zh) | 2011-08-31 |
| BRPI0913783A2 (pt) | 2016-11-01 |
| EP2349311A1 (en) | 2011-08-03 |
| JP2012504161A (ja) | 2012-02-16 |
| CA2738622C (en) | 2016-10-18 |
| ES2435438T3 (es) | 2013-12-19 |
| NZ571665A (en) | 2011-01-28 |
| JP2016026157A (ja) | 2016-02-12 |
| AU2009300442A1 (en) | 2010-04-08 |
| WO2010039048A1 (en) | 2010-04-08 |
| US10232010B2 (en) | 2019-03-19 |
| AU2009300442B2 (en) | 2014-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016026157A (ja) | 放射線被曝の処置のための組成物および方法 | |
| US20200188515A1 (en) | Compositions Containing Nucleosides and Manganese and Their Uses | |
| CN107669692A (zh) | Mpla在制备电离辐射致肠道损伤防治药物中的应用 | |
| ES2647584T3 (es) | Método para producir vacunas que comprende la irradiación de microorganismos en una composición que comprende aminoácidos y ortofosfato de manganeso | |
| Yi et al. | Emerging strategies based on nanomaterials for ionizing radiation-optimized drug treatment of cancer | |
| Prasanna et al. | Modification of WR-2721 radiation protection from gastrointestinal injury and death in mice by 2-mercaptopropionylglycine | |
| JP6150374B2 (ja) | 放射線被ばく治療剤及び放射線被ばく治療方法 | |
| Krahenbuhl et al. | Effects of Corynebacterium parvum treatment and Toxoplasma gondii infection on macrophage-mediated cytostasis of tumour target cells | |
| JP5553306B2 (ja) | 放射線障害防護剤 | |
| Srinivasan et al. | High-dose antibiotic therapy is superior to a 3-drug combination of prostanoids and lipid A derivative in protecting irradiated canines | |
| CN101505781A (zh) | 作为辐射防护物质的乳铁蛋白 | |
| Rojas et al. | Effects of radiomodifiers on high and low LET responses in vivo | |
| AU2016222458B2 (en) | Compositions containing Nucleosides and Manganese and their Uses | |
| Skicki-Mullen et al. | Interferon-induced inhibition of Moloney sarcoma virus-transformed cells: requirement for T-cells | |
| CN118021939A (zh) | Bmp4蛋白或其衍生物在制备药物中的用途 | |
| CN108904479A (zh) | 二烯丙基一硫在制备辐射引起白细胞减少的药物中的应用 | |
| 박은진 | Radioprotective Activity of Eckol in Gamma ray-irradiated Mice | |
| AU2014200523A1 (en) | Compositions containing Nucleosides and Manganese and their Uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120928 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140402 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141202 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150417 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150814 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150831 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20151023 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160608 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161018 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161129 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6053283 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |